Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Los Bonos 1 (no aplicable en España), 2 (Marcas y Diseños) y 3 (patentes nacionales, patentes europeas, informes tecnológicos de patentes y búsquedas retrospectivas) se encuentran cerrados desde el 20/08/2025. La solicitud del Bono 4 sigue abierta. Más adelante se informará sobre la reapertura de estos Bonos
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
149
resultados
Última actualización
17/09/2025 [07:15:00]
Resumen de: WO2025186660A1
The present invention relates to second-generation vaccine against COVID-19 to abrogate or diminish the binding of the SARS-CoV-2 spike (S) protein, or part of it, to the human angiotensin-converting enzyme 2 (hACE2). Such vaccines present several advantages as to avoid pathways of immune dysregulation activated following S protein/hACE2 interaction while maintaining the ability to elicit a strong and robust antibody neutralization response to SARS-CoV-2. The invention relates also to the use of the S protein for therapeutic uses and for vaccines in the prevention or treatment of SARS-CoV-2 infection or conditions or disorders resulting from such infection.
Resumen de: WO2025189041A1
Described herein are methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.
Resumen de: WO2025189138A1
An affinity membrane separator is provided that includes a separation substrate with a plurality of peptide ligands positioned thereon. The peptide ligands preferentially bind to one of a nucleic acid product and a waste nucleic acid product, e.g., produced by a mRNA synthesis bioreactor. The peptide ligands include fewer than 20 residues and at least one defined secondary structure, and have a global charge greater than about 1 and at least one lysine, arginine, or glutamine residue in order to preferentially bind ds-RNA relative to ss-RNA, or a global charge less than about 0 and at least one serine or asparagine residue in order to preferentially bind ss-RNA relative to ds-RNA. Peptide ligands can advantageously bind to ds-RNA byproducts from the production of ss-RNA vaccines, e.g., against SARS-CoV-2, while allowing the ss-RNA vaccines themselves to pass through the separator, providing an efficient system for production of purified ss-RNA vaccine products.
Resumen de: WO2025187767A1
One problem to be addressed by the present invention is to provide a drug which is capable of suppressing the proliferation of SARS-CoV-2 with high efficiency. Another problem to be addressed by the present invention is to provide a drug which exhibits an inhibitory effect on a wide range of coronaviruses and thereby can immediately respond to the pandemic of unknown SARS-CoV-2 mutants and new types of coronaviruses which could happen in the future. Provided is an oligonucleotide or a pharmaceutically acceptable salt thereof, wherein: the oligonucleotide comprises an oligonucleotide that is composed of 17-30 nucleotides and comprises a nucleotide sequence and is complementary to a region lying between a nucleotide located at position-13520 to a nucleotide located at position-13550 in SARS-CoV-2 RNA genome comprising the nucleotide sequence represented by SEQ ID NO: 1; and the oligonucleotide is a mixmer and is capable of inhibiting the viral proliferation of coronaviruses, wherein the 5'-end and/or the 3'-end of the oligonucleotide may be chemically modified. Also provided is a drug comprising the oligonucleotide or a pharmaceutically acceptable salt thereof.
Resumen de: US2025282832A1
A chimeric nucleotide sequence that corresponds to an encoded fusion protein comprising a polyepitope resulting from selecting and juxtaposing multiple epitopes from a coronavirus protein to induce an immune response in mammals. In one embodiment, said fusion protein comprises: a) a first peptide consisting of epitopes found in the amino acid sequence of replicase polyprotein 1ab (PR1ab); b) a first spacer; c) a modified form of herpes simplex virus type 1 (HSV-1) glycoprotein D (gD). In one embodiment, the replicase polyprotein is defined by SEQ ID NO: 96 flanked by a gD fragment comprising the amino acid sequence defined by SEQ ID NO: 98 in the N-terminal portion and another gD fragment comprising the amino acid sequence defined by SEQ ID NO: 100 in the C-terminal region. Use of the fusion protein has surprising results in inducing cellular and humoral immune responses against coronavirus, SARS-COV-2, and related viruses.
Resumen de: US2025282831A1
The present invention relates to a mutated SARS-COV-2 spike protein, a variant or fragment thereof or an mRNA or DNA encoding them for use in the prevention of COVID-19.
Resumen de: US2025283881A1
The present disclosure provides systems and processes to screen for SARS-CoV-2. This disclosure teaches specific (and different) workable ranges for starting materials in a screening process for different SARS-CoV-2 variants (e.g., the Washington isolate, Alpha variant, Gamma P.1 variant, Beta variant, Iota variant, Delta variant, Omicron BA.1 variants, etc.). As shown herein, each variant has a different combination of starting materials and incubation periods, which further demonstrates the unpredictability of success that is associated with the disclosed systems and the disclosed processes. To be clear, the general ELISA process is well known by those having skill in the art. However, what is neither well known nor intuitive are the specific parameters associated with different process steps within ELISA. Those specific parameters are the subject of this disclosure.
Resumen de: AU2024230449A1
The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.
Resumen de: US2025283880A1
The present invention provides a sensitizer for immunochromatographic assay capable of detecting novel coronavirus (SARS-CoV-2) IgM antibodies and/or IgG antibodies with high sensitivity, and an assay using the sensitizer. Specifically, the present invention provides a sensitizer for immunochromatographic assay for novel coronavirus (SARS-CoV-2) IgM antibodies and/or IgG antibodies as assay target substances, that contains a polymer represented by the following formula 4:wherein m, n, and p are each a constitutional unit number, an m:n:p is 100 to 30:0 to 70:0 to 50.
Resumen de: US2025283882A1
The present disclosure relates to the use of DNA-peptide hybrid molecules to detect target molecules in a sample. In some embodiments, the DNA-peptide hybrid molecules comprise target-specific binding peptides which selectively bind to a target molecule. Kits comprising DNA-peptide hybrid molecules are also provided.
Resumen de: LU509898B1
The present invention belongs to the technical field of traditional Chinese medicine, and discloses a traditional Chinese medicine prescription for preventing and treating COVID-19, which is composed of the following weight components: 9 to 15 grams of wild chrysanthemum, 6 to 15 grams of Artemisia annua, 10 to 20 grams of mint, and 3 to 15 grams of Elsholtzia. The formula of the present invention is scientific and reasonable, and the drug effect reaches the affected part directly, which can reduce fever, relieve cough, and resolve phlegm, quickly relieve sore throat, dry and hot throat, and peeling lips, and can effectively prevent and inhibit the occurrence and recurrence rate of COVID-19, and at the same time has the advantages of fast effect and fast recovery of physical strength.
Resumen de: US2025281867A1
A purification device and method for treating air flow of an air handling system. A high-efficiency particulate air (HEPA) filter can be disposed across a plenum of the purification device that is configured for passage of the air flow. A heater can be disposed across the plenum and may have a permeable barrier that is configured to allow the air flow to pass therethrough. A metal material of the permeable barrier can be connected in electrical communication to a supplied power. The permeable barrier can have an active surface area configured to interact with a pathogen of the air flow and can be heated by the supplied power to a surface temperature directed to kill the pathogen.
Resumen de: US2025281393A1
The present invention relates to non-psychoactive cannabinoid-comprising compositions, said compositions comprising cannabidiol (CBD) formulated for application in a body cavity, such as a gel for intranasal application. Said composition comprises CBD; glycol(s); emulsifier(s), including non-ionic emulsifier(s); NaCl; panthenol; hyaluronic acid/salt; phytic acid and water, and optionally one or more of gelling agent, allantoin, and/or pH regulator. Such compositions can be used in the context of protection against pathogens and/or in reduction of ingress of infectious and/or irritating agents such as dust, pollen, microorganism(s), bacteria, fungi, and/or virus, such as COVID-19.
Resumen de: US2025281606A1
The present invention relates to a pharmaceutical composition comprising therapeutically effective amount of Cannabidiol for administration with a Covid-19 vaccine to a mammal/human to sustain and/or enhance effect of vaccine. Further the invention relates to methods to sustain and/or enhance effect of a Covid-19 vaccine in a mammal/human by administering to such a mammal/human a pharmaceutical composition comprising a therapeutically effective amount of Cannabidiol with a Covid-19 vaccine.Administration of Cannabidiol with vaccine can be of following types: i) before administering Covid-19 vaccine; or ii) along with Covid-19 vaccine; or iii) after administering Covid-19 vaccine; or iv) any combination of i, ii and iii including before, along with and after administering Covid-19 vaccine.
Resumen de: US2025281601A1
The invention relates to vaccination of human subjects, in particular elderly, against bacterial infections, wherein the bacterial infection is not pneumococcal, and COVID-19 infections.
Resumen de: WO2024096742A1
The invention is in the field of medical treatment, and relates to a method for treating SARS-CoV-2 infections. In particular, the present invention relates to methods for prophylactic and/or therapeutic treatment of betacoronavirus infections, in particular, SARS-CoV-2 infections by means of intranasal administration or oral inhalation of polypeptides.
Resumen de: WO2024096743A1
The invention is in the field of medical treatment, and relates to a method for treating SARS-CoV-2 infections. In particular, the present invention relates to methods for prophylactic and/or therapeutic treatment of betacoronavirus infections, in particular, SARS-CoV-2 infections by means of intranasal administration or oral inhalation of antibodies.
Resumen de: EP4613330A1
An mRNA molecule is disclosed. The mRNA molecule contains a polynucleotide encoding an M1R antigen of Mpox and a polynucleotide encoding an RBD antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and further contains a polynucleotide encoding an A35R antigen of Mpox. The present disclosure further discloses an application of the mRNA molecule in the preparation of an mRNA vaccine against Mpox or SARS-CoV-2. Compared to an mRNA vaccine encoding separately corresponding antigens, the mRNA vaccine encoding a fusion antigen provided by the present disclosure can induce considerable or even higher-level neutralizing antibody responses against Mpox and SARS-CoV-2, and provides 100% immune protection against the lethal challenge of ectromelia virus. The vaccine only needs to synthesize a single mRNA molecule for the encapsulation within lipid nanoparticles. Therefore, the single-component fusion mRNA vaccine has a wider application prospect than multivalent mRNA vaccine compositions.
Resumen de: JP2024020274A
To provide a drug with antiviral activity against SARS-CoV-2, which can be used for the treatment of a related disease caused by the infection of SARS-CoV-2.SOLUTION: There is provided a substituted aminopropionate compound represented by formula I, a geometric isomer, and a pharmaceutically acceptable salt thereof, a solvate thereof and/or a hydrate thereof, for treating diseases or infections caused by SARS-CoV-2.SELECTED DRAWING: Figure 1
Resumen de: EP4614150A1
The present disclosure provides systems and processes to screen for SARS-CoV-2. This disclosure teaches specific (and different) workable ranges for starting materials in a screening process for different SARS-CoV-2 variants (e.g., the Washington isolate, Alpha variant, Gamma P.1 variant, Beta variant, Iota variant, Delta variant, Omicron BA.1 variants, etc.). As shown herein, each variant has a different combination of starting materials and incubation periods, which further demonstrates the unpredictability of success that is associated with the disclosed systems and the disclosed processes. To be clear, the general ELISA process is well known by those having skill in the art. However, what is neither well known nor intuitive are the specific parameters associated with different process steps within ELISA. Those specific parameters are the subject of this disclosure.
Resumen de: US2025276005A1
The invention provides a method for treating SARS-COV-2 by administering an effective amount of pectin polysaccharides to a subject in need thereof.
Resumen de: US2025277788A1
A SARS-COV-2 N protein-specific single-chain antibody, a fusion protein, and use thereof are provided. The antibody includes a heavy chain variable region VH, a linker and a light chain variable region VL which are connected in sequence; the amino acid sequence of the heavy chain variable region VH is set forth in SEQ ID NO: 4; and the amino acid sequence of the light chain variable region VL is set forth in SEQ ID NO: 6. Compared with the conventional ELISA detection, the fusion protein can greatly shorten the detection time, can catalyze the substrate to generate a color reaction which can be recognized by naked eyes, and can perform detection without special instruments.
Resumen de: US2025276979A1
The present disclosure relates to compounds of Formula I:and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
Resumen de: US2025277258A1
This disclosure relates to heteromultivalent nucleic acid-functionalized surfaces, such as particles, and uses in optimizing hybridization specificity for targets containing one, two, or more mutations. In certain embodiments, heteromultivalent hybridization enables fine-tuned specificity for a single SNP and dramatic enhancements in specificity for two non-proximal SNPs empowered by cooperative binding. In certain embodiments, use of specified oligo lengths, spacer lengths, and binding orientation are contemplated. In certain embodiments, this disclosure provides for methods of discrimination between heterozygous cis and trans mutations and between different strains of a virus, e.g., the SARS-CoV-2 virus.
Nº publicación: US2025277021A1 04/09/2025
Solicitante:
REGENERON PHARMACEUTICALS INC [US]
Regeneron Pharmaceuticals, Inc
Resumen de: US2025277021A1
The present invention provides methods for preventing and treating cardiac dysfunction, including cardiomyopathy and heart failure. The methods of the invention feature the administration of an antagonist of Activin A, e.g., a therapeutically effective amount of an antibody that binds to and reduces or neutralizes the activity of human Activin A. The methods of the invention are useful in preventing and treating cardiac disease from multiple causes, including viral disease, e.g., COVID-19.
BOPI
Sede Electrónica
